Edward Nash, an analyst from Canaccord Genuity, maintained the Buy rating on Corcept Therapeutics (CORT – Research Report). The associated price target remains the same with $142.00.
Edward Nash has given his Buy rating due to a combination of factors that suggest a positive outlook for Corcept Therapeutics. One key reason is the company’s confidence in its financial guidance for FY2025, which remains strong despite anticipated seasonal weaknesses in the first quarter due to prior-authorization requirements and a previous distribution issue. The management’s assurance that these challenges have been accounted for in their projections reinforces the credibility of their revenue estimates.
Additionally, Corcept’s ongoing efforts to advance its pipeline, particularly with the positive Phase III ROSELLA trial, contribute to the optimistic view. The company is actively working towards submitting a New Drug Application (NDA) to the FDA, and further updates are expected during upcoming investor events. Moreover, the increasing usage of Korlym, despite the presence of a lower-priced generic, suggests a robust demand that could offset potential pricing pressures. These factors collectively support Edward Nash’s Buy rating for Corcept Therapeutics.
According to TipRanks, Nash is a 5-star analyst with an average return of 9.9% and a 42.55% success rate. Nash covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, Verona Pharma, and Travere Therapeutics.
In another report released on April 25, Piper Sandler also reiterated a Buy rating on the stock with a $131.00 price target.